Clinical trials: Endocrine System Disorder
Turner Syndrome, Renal Insufficiency, Chronic
Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAq
The main purpose of this study is to establish an optimal monitoring regimen in NutropinAq treated children, using newly developed capillary blood spot IGF-1 measurement technology.
- Conditions
- Turner Syndrome, Renal Insufficiency, Chronic, Pituitary Diseases, Dwarfism
- Trial name
- OPTIMA (NCT00234533)
- Testing
- Somatropin (rDNA origin)
- Where
- 45 sites in Belgium, Czechia and 12 more
- Volunteers
- 251 people
- Sponsor
- Ipsen
Hypoglycemia Unawareness, Type 1 Diabetes
Intra-nasal Naloxone for Treatment of Impaired Awareness of Hypoglycemia
This is a single center, single-blind randomized cross over design trial that will compare the impact of intra-nasal naloxone vs.
- Trial name
- NCT02700048
- Testing
- intra-nasal naloxone, Intra-nasal saline
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Obstructive Sleep Apnea, Type 2 Diabetes
Effects of Continuous Positive Airway Pressure (CPAP) Treatment on Glucose Control in Patients With Type 2 Diabetes
The overall goal of the proposed protocol is to rigorously test the hypothesis that CPAP treatment has beneficial effects on glycemic control in patients with both type 2 diabetes (T2DM) and obstructive sleep apnea (OSA).
- Trial name
- CPAP (NCT01136785)
- Testing
- active CPAP Therapy
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Chicago
Epithelial Ovarian Cancer, Fallopian Tube Cancer
A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)
This is an open label Phase 2, 2-stage, 2-cohort study to evaluate rucaparib in combination with nivolumab in patients with high-grade serous or endometroid ovarian cancer.
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, High Grade Serous Carcinoma
- Trial name
- NCT03824704
- Testing
- Rucaparib, Nivolumab
- Where
- 5 sites in United States
- Volunteers
- 1 people
- Sponsor
- pharmaand GmbH
Short Stature
Individualizing Dose of Growth Hormone to Maintain Normal Growth Velocity After Fulfilled Catch up Growth in Children
The objective was to study whether normal growth velocity can be maintained with adapted GH dosage in GH treated prepubertal children who have responded to GH treatment with fulfilled catch up growth (=difference to target height…
- Trial name
- MAINTENANCE (NCT02879747)
- Testing
- Genotropin
- Volunteers
- 99 people
- Sponsor
- Göteborg University
Ovarian Neoplasms
A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer
The purpose of this study is to determine if participants with platinum-refractory or platinum-resistant advanced ovarian cancer have a better outcome when treated with Olaratumab (IMC-3G3) in combination with Liposomal…
- Trial name
- NCT00913835
- Testing
- Olaratumab, liposomal doxorubicin
- Where
- 6 sites in United States
- Volunteers
- 125 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Diabetes Homelessness Medication Support Program in Spanish
This single-arm trial of the Diabetes Homeless Medication Support intervention for Spanish-speaking people (n=12) will test the perception and feasibility of anticipated study procedures.
- Trial name
- DH-Spanish (NCT05819749)
- Testing
- Diabetes Homelessness Medication Support Program in Spanish
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Hennepin Healthcare Research Institute
Type 1 Diabetes
Outpatient Study to Evaluate Safety and Effectiveness of the Low Glucose Suspend Feature
Introduction: The purpose of the pivotal In Home study is to collect clinical data on the safety and efficacy of the Paradigm LGS System in the actual use environment and by the intended use population.
- Trial name
- ASPIRE (NCT01497938)
- Testing
- Medtronic MMT-754 Veo Insulin pump testing Low Glucose Suspend (LGS) feature, Medtronic (NO LGS FEATURE ) using Paradigm® Revel™2.0 Pump
- Where
- 17 sites in United States
- Volunteers
- 247 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 2 Diabetes, Sedentary Behavior
Technology Based Sedentary Reduction Intervention in Patients With Type 2 Diabetes
The purpose of this study is to develop and test an 8-week sedentary behavior reduction intervention ("Sit Less" program) for patients with type 2 diabetes.
- Conditions
- Type 2 Diabetes, Sedentary Behavior, Physical Activity
- Trial name
- NCT05691452
- Testing
- Sit Less Program
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Diabetes Mellitus, Leg Injuries
Prosthetic Components and Stability in Amputee Gait
The biomechanics of changing direction while walking has been largely neglected despite its relevancy to functional mobility. In addition, an increased risk of injury can be associated with turning due to a decrease in stability.
- Conditions
- Diabetes Mellitus, Leg Injuries, Traumatic Amputation
- Trial name
- NCT00167778
- Testing
- Transverse plane rotation adaptor pylon, Rigid pylon
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- US Department of Veterans Affairs
Adrenal Insufficiency
Once-daily Oral Modified Release Hydrocortisone in Patients With Adrenal Insufficiency
This is a randomised, controlled, open, two-armed, two-period cross-over, multi-centre phase II/III study to assess the safety, tolerability and pharmacokinetics of once-daily oral modified-release hydrocortisone in comparison to…
- Trial name
- NCT00915343
- Testing
- hydrocortisone (modified release), oral tablet 20 and 5 mg, Hydrocortisone, oral tablet, 10 mg
- Volunteers
- 64 people
- Sponsor
- Shire
Advanced Solid Tumors, Triple Negative Breast Cancer
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)
The purpose of this study is to determine the safety and efficacy of combination therapy with pembrolizumab (MK-3475) and lenvatinib (E7080/MK-7902) in participants with triple negative breast cancer (TNBC), ovarian cancer…
- Conditions
- Advanced Solid Tumors, Triple Negative Breast Cancer, Ovarian Cancer, Gastric Cancer
- Trial name
- NCT03797326
- Testing
- Pembrolizumab, Lenvatinib
- Where
- 88 sites in United States, Argentina and 15 more
- Volunteers
- 611 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
Study to Assess the Safety and Tolerability After Multiple Oral Doses of AZD1656 in Patients With Type 2 Diabetes Mellitus Treated With Metformin
The purpose of this study is to assess the 1 month safety and tolerability after multiple oral doses of AZD1656 in patients with Type 2 Diabetes Mellitus Treated with Metformin
- Trial name
- NCT00817778
- Testing
- AZD1656
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- AstraZeneca
Diabetic Foot Ulcer
MIRODERM H2H DFU Study
This study will assess the ability of MIRODERM to heal difficult diabetic foot ulcers within 12 weeks of treatment.
- Trial name
- H2H-DFU (NCT03232333)
- Testing
- Biologic wound graft
- Where
- 9 sites in United States
- Volunteers
- 53 people
- Sponsor
- Miromatrix Medical Inc.
Type 2 Diabetes
A Study of LY3437943 in Participants With Type 2 Diabetes
The main purpose of this study is to evaluate the efficacy and safety of LY3437943 in participants with type 2 diabetes (T2D) who failed to achieve adequate glycemic control on diet and exercise alone or on a stable dose of…
- Trial name
- NCT04867785
- Testing
- LY3437943, Dulaglutide
- Where
- 43 sites in United States, Puerto Rico
- Volunteers
- 281 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study
This is a randomized, double-blind, double-dummy, placebo-controlled, cross over design trial with empagliflozin compared to placebo that is added to open-label ramipril.
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Obesity
- Trial name
- NCT02632747
- Testing
- Empagliflozin, ramipril
- Where
- Canada
- Volunteers
- 31 people
- Sponsor
- Boehringer Ingelheim
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer
Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer
This randomized phase II trial is studying bevacizumab, gemcitabine, and cetuximab to see how well they work compared to bevacizumab, gemcitabine, and erlotinib in treating patients with advanced pancreatic cancer.
- Conditions
- Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer
- Trial name
- NCT00091026
- Testing
- cetuximab, gemcitabine hydrochloride, bevacizumab
- Where
- United States
- Volunteers
- 143 people
- Sponsor
- National Cancer Institute (NCI)
Type 2 Diabetes, Coronary Artery Disease
Effects of Linagliptin on Endothelial Function
This study is planned to evaluate if linagliptin can improve endothelial function in patients with type 2 diabetes mellitus. In addition, the effect of linagliptin on arginine bioavailability ratios and postchallenge glycaemic…
- Trial name
- NCT02350478
- Testing
- Linagliptin
- Where
- Austria
- Volunteers
- 49 people
- Sponsor
- Medical University of Graz
Diabetes Mellitus, Type 2
Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone
The objective of the current study is to investigate the efficacy, safety and tolerability of BI 1356 (Linagliptin) (5 mg / once daily) compared to placebo given for 24 weeks as initial combination therapy with pioglitazone 30 mg…
- Trial name
- NCT00641043
- Testing
- Linagliptin + pioglitazone (30 mg)
- Where
- 43 sites in Austria, Greece and 5 more
- Volunteers
- 389 people
- Sponsor
- Boehringer Ingelheim
Head and Neck Neoplasms
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
The purpose of this trial is to estimate progression free survival in patients with recurrent or metastatic head and neck cancer that have not received chemotherapy in this setting.
- Trial name
- NCT01057589
- Testing
- Pemetrexed, Cetuximab, Cisplatin
- Where
- 13 sites in Belgium, France and 4 more
- Volunteers
- 66 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.